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ABSTRACT: The selective oxygenation of nonactivated carbon atoms is
an ongoing synthetic challenge, and biocatalysts, particularly hemoprotein
oxygenases, continue to be investigated for their potential, given both
their sustainable chemistry credentials and also their superior selectivity.
However, issues of stability, activity, and complex reaction requirements
often render these biocatalytic oxygenations problematic with respect to
scalable industrial processes. A continuing focus on Cytochromes P450
(P450s), which require a reduced nicotinamide cofactor and redox
protein partners for electron transport, has now led to better catalysts and
processes with a greater understanding of process requirements and
limitations for both in vitro and whole-cell systems. However, the
discovery and development of unspecific peroxygenases (UPOs) has also
recently provided valuable complementary technology to P450-catalyzed reactions. UPOs need only hydrogen peroxide to effect
oxygenations but are hampered by their sensitivity to peroxide and also by limited selectivity. In this Perspective, we survey recent
developments in the engineering of proteins, cells, and processes for oxygenations by these two groups of hemoproteins and evaluate
their potential and relative merits for scalable reactions.
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■ INTRODUCTION
The selective oxygenation of nonactivated carbon centers
remains a significant challenge in organic chemistry and has
been addressed over several decades using either micro-
organisms or enzymes.1,2 Biocatalyzed oxygenations have
advantages over chemical reagents that accomplish similar, if
less selective, transformations: They occur at ambient temper-
atures and pH and do not utilize harmful metals such as
chromium. However, it is arguably their selectivity that makes
them so highly prized. The observation that the fungus Rhizopus
spp. hydroxylated progesterone 1 to 11α-hydroxyprogesterone 2
(Scheme 1) in a regio- and stereoselective manner was a
revelation as far back as 1952,3 and the further development of
whole-cell fungal biocatalysts for preparative scale oxygenations
held, and continues to hold, much promise.4
In another notable example, Hauer and colleagues used a
chemically mutated strain of the fungus Beauveria bassiana to
hydroxylate the pesticide precursor (R)-phenyl propionic acid 3
to hydroxyphenylpropionic acid 4 (HPOPS) at the 100 m3 scale
with a productivity of 7 g L−1 d−1 (Scheme 1).5 These and other
advances created an expectation that biocatalytic oxygenation
would be a breakthrough technology for the selective synthesis
of pharmaceuticals, agrochemicals, drug metabolites, and also
bulk chemicals. Enthusiasm would have been increased by the
revolution in molecular biology and genomics in subsequent
years, which revealed a vast number of gene sequences encoding
“hydroxylase” enzymes of many types and also the genetic
engineering tools to express them in heterologous hosts and to
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Scheme 1. Examples of Scalable Hydroxylations by Whole
Cells of Filamentous Fungi
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improve their catalytic abilities using protein engineering.
Hemoproteins have, for the most part, been the enzymes of
choice for selective oxygenations, and indeed, the cytochromes
P450 (P450s),6,7 a large family of hemoproteins, are responsible
for catalyzing the reactions shown in Scheme 1. The diversity of
chemical reactions catalyzed by hemoproteins means that, in
theory, a wide range of biotransformations to valuable products
should be achievable, in modes similar to those achieved in the
1950s with steroids, if techniques could be developed to express
these enzymes in generally regarded-as-safe (GRAS), easy-to-
grow host organisms. However, despite the number of genes,
and the tools available to clone, express, and mutate them, the
number of scalable industrial biocatalytic oxygenations, outside
those that exploit native strains or those altered by “Classical
Strain Improvement” (CSI, using mutagens), remains low. In
this Perspective, the recent (since 2014) literature on progress
toward scalable biooxygenations using hemoprotein oxygenases
is surveyed. Advances in protein engineering and process
technology for exploiting recombinant P450s in vitro and in
whole cells are considered. These developments will then be
contrasted with parallel work on another class of hemoproteins,
the unspecific peroxygenases (UPOs),8,9 which have emerged as
a complementary set of enzymes with the potential for scalable
oxygenation reactions.
■ P450s AND UPOs: A BRIEF INTRODUCTION
Before considering recent developments, it is useful to briefly
contrast the biochemical characteristics of P450s and UPOs. In
both enzymes, oxygenation of a carbon atom is accomplished by
an iron(IV) oxo species (“Compound I”, Scheme 2) formed at
the heme iron within the active site. The mechanism of
formation of this species differs between the two enzyme classes
and there are fundamental differences in the active site structure
that enable Compound I to be formed in each case. In P450s,
following substrate binding, and a one electron reduction of Fe3+
to Fe2+, the iron reacts with dioxygen, and the further delivery of
Scheme 2. Formation of Compound I (Boxed) in P450s and UPOs
Figure 1. (A) Active site of P450cam in complex with camphor (cam) (PDB 1CPP). (B) Active site ofAgrocybe aegerita (AaeUPO) complexed with 1-
naphthol (nol) (PDB 6EKY). One ligand from these coordinates has been selected for clarity.
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another single electron enables the cleavage of the dioxygen
bond via an iron peroxo complex, yielding water as a byproduct,
to give Compound I (Scheme 2).7,10
In UPOs, reaction of the iron with hydrogen peroxide (H2O2)
gives a ferric peroxo complex directly and this also cleaves to give
Compound I (Scheme 2).8,11,12 In both P450s and UPOs, the
heme iron is ligated at the axial position by a cysteine residue.
However, the mechanism of O−O bond cleavage for
Compound I formation is assisted by different residues in the
active site of each enzyme (Figure 1): In the well-studied
P450cam, this is thought to be catalyzed by a threonine residue
T252 (Figure 1A);13 and in UPOs it is thought to be catalyzed
by a glutamate E196, situated above the heme (Scheme 2; Figure
1B).14
In P450s, the formation of Compound I depends on the
delivery of electrons to the heme by electron transport proteins,
the identity and nature of which are diverse.15 In the most
common systems, electrons are delivered from a nicotinamide
cofactor NAD(P)H, via either a flavin-containing ferredoxin
reductase (FdR) and an iron−sulfur containing ferredoxin (Fd)
(“Class I”,15 found in bacteria) or a flavin-containing
cytochrome P450 reductase (CPR) alone (“Class 2”; in fungi,
plants, and mammals). The requirement for both expensive
nicotinamide cofactors and these electron-transfer proteins
renders the application of recombinant P450s in vitro somewhat
complex, as more than one gene must be expressed, and there is
a lack of efficiency in electron transfer, giving rise to what is
termed “uncoupling”. In some cases, the electron transport
proteins and hemoprotein can be naturally fused within one
polypeptide, simplifying the problems of expression and
reconstitution in vitro. The most famous example is cytochrome
P450BM3 (CYP101A2) from Bacillus megaterium,16 which is
probably the most studied and engineered P450 for process
applications for this reason. Some P450s are also able to operate
in a “peroxygenase”mode, in which the addition of H2O2 to the
heme domain in the absence of electron transfer proteins leads
to the formation of Compound I at the heme, and enables
hydroxylation to occur.17 Indeed some P450s are known to
operate naturally in peroxygenase mode,18,19 and have been the
focus of considerable recent interest.
The H2O2-dependent generation of Compound I is also
employed by UPOs, which, consequently, are not dependent for
activity on NAD(P)H or electron transfer proteins. UPOs are
secreted enzymes expressed in Nature from fungi and are
thought to form part of the biocatalytic arsenal deployed for the
degradation of complex biomolecules such as lignin.8,9 UPOs,
which were first identified by Hofrichter et al. in 2004,20 were
initially thought to be chloroperoxidases, another hemoprotein
that deploys Compound I for oxygenations, although in that case
the oxidation of halide ions to form X+ ions that are employed in
the electrophilic halogenation of largely aromatic substrates.
However, research on their structure and biochemistry has
revealed the significantly greater oxidative power of UPOs, in
that they are also capable of the hydroxylation of a wide variety
of organic compounds. However, as with P450s, there are issues:
UPOs display a sensitivity to the H2O2 that they employ to make
Compound I. There is also a comparative lack of selectivity that
leads to multiple products with substrates having comparably
susceptible carbon centers. UPOs, being eukaryotic enzymes,
are also glycosylated, and most examples appear to require
glycosylation for full activity, so heterologous expression in most
cases has been restricted to yeasts such as Saccharomyces
cerevisiae and Pichia pastoris.
The apparent advantages and disadvantages of P450s and
UPOs as oxygenase catalysts with the potential for scalable
reactions are listed in Table 1. In 2015, Lundemo and Woodley
summarized the challenges of using P450 systems at scale,21
some of which may apply to UPOs. In their summary,
“biological” considerations included biocatalyst stability, to
maximize the benefits of the best turnover numbers seen in P450
reactions, robust heterologous hosts for whole-cell reactions,
and maximization of coupling within the electron transfer
system. “Process” factors to be considered included ease of
product recovery and substrate and product characteristics and
how these inform the choice of system for scale-up.
In this Perspective, we will compare and contrast advances
that have addressed the limitations of each enzyme type and that
look forward to their wider application in the future. We show
that some of the issues have been addressed directly for P450
catalysis using both in vitro and whole-cell systems but that
sometimes reaction outcomes may be better realized through
the application of the alternative UPOs.
■ CYTOCHROMES P450
Enzyme Engineering for In Vitro Applications
The generation of useful activity is the first step in developing a
biocatalytic process, and new activities of P450s, both natural22
and non-natural,23 continue to be discovered. The group of
Arnold has, for example, shown that P450s can be engineered for
cyclopropanation24 and intermolecular amination25 reactions
and the hydroxylation of silanes.26 However, the focus of many
projects has been the in vitro evolution of enzymes,
predominantly P450BM3, which possess the qualities of high
native activity and fusion of reductase and hemoprotein
domains, for selective oxygenation reactions.
Hydroxylation of Steroids by P450BM3 Mutants
Given the significance of steroids to the pharmaceutical industry
and the history of P450s in steroid transformations, they remain
a focus for P450 evolution. Libraries of P450BM3 variants were
assessed for the selective hydroxylation of dehydroepiandroster-
one (DHEA) 5, testosterone (TST) 8, and androstenedione
(AD) (Scheme 3).27
A comparison of P450BM3 and the steroid C19-demethylase
CYP19A1 suggested glycine scanning as an effective approach to
the discovery of mutants with improved regioselectivity. For
example, mutant “K19” F87A/A82M/I263G/A328G was 93%
selective for generating 7-α-hydroxy DHEA 6, whereas “R19”
F87A/A184I/T260G/A328G was 97% selective for 7-β-
hydroxy DHEA 7 (where K19 and R19 represent starting
Table 1. Overview of Catalytic Characteristics of P450s and
UPOs
characteristic P450s UPOs
require electron transport proteins or domains yes no
requirement for nicotinamide cofactors and
cofactor recycling
yes no
uncoupling reactions yes no
use H2O2 sometimes yes
sensitivity to H2O2 yes yes
expression in E. coli yes some
examples
expression in yeasts yes yes
whole-cell systems for hydroxylation yes no
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points of already constructed mutants). Mutations at positions
260 and 263 were thought to distort the I-helix in the heme
domain of P450BM3, creating space for complementary steroid
binding modes. These experiments were performed at the 2 mM
[substrate] scale in 200 mL and employed cofactor recycling. Li
and co-workers started with the triple variant F87G/A328G/
A330W and targeted 15 further sites at or near the active site for
mutagenesis.28 Variant “LG-23”, with 14 mutations, was 83%
selective for the production of 7β- hydroxytestosterone.
Reactions were scaled up to 1 mM [substrate] in 50 mL using
freeze-thawed cells, giving products in up to 82% yield. 7β-
Selectivity was also observed for LG-23 with four other steroids
including nandrolone. The same group used an in vitro
evolution approach based on mutability landscapes, structure,
and modeling to create variants that targeted the 16-position of
testosterone.29 Mutant WIFI-WC (R47W/S72I/A82F/S72I-
Y51W/L181C) was 96% selective for the production of 16α-
testosterone 9, whereas WWV-QRS (R47W/A82W/F87V-
L181Q/T436R/M177S) was 92% selective for the 16β-isomer
10. Scaled-up reactions using freeze-thawed cells at 1 mM
[substrate] in 100mL gave 23.3 and 7.7 mg of products 9 and 10
with yields of 77% and 27%, respectively.
Aromatic Hydroxylations by P450BM3 Mutants
Reetz and co-workers engineered P450BM3 mutants for the
oxidation of benzene through phenol to hydroquinone.30
Variant A82F/A328F converted phenol to hydroquinone, with
a turnover rate of 590 min−1, but also converted benzene to
hydroquinone with 90% conversion. The mutant was employed
in whole cells at the 20 mL scale in 10 mM benzene, giving the
product in 55% yield. The conversion of benzene to phenol was
also accomplished by Shoji and co-workers using the “decoy”
molecule 3-CPPA-Pip-Phe to stimulate the hydroxylation of the
substrate.31 Wild-type (wt) P450BM3 in whole cells of
Escherichia coli converted 20 mM benzene to phenol at the 1
mL scale, with a total turnover number (TTN) of 54 500, with
no conversion to hydroquinone.
A range of anilides was transformed by P450BM3 variants to
phenols in studies by O’Hanlon et al.32 Trifluoroacetanilide 11
was transformed to phenol 12 with 100% conversion by enzyme
“KSK19/AIAI” in vitro at the 0.079 mol scale in 30 mL, giving a
yield of 51% (Scheme 4).
The herbicidal N-sulfonylanilide 13 was hydroxylated to 14
by the P450BM3 mutant “RP/FV/EV” at the 0.9 mmol scale in
34 mL in 13% yield. Dennig and co-workers showed that variant
“M3” (R47S/Y51W/A330F/I401M) converted mesitylene 15
(1,3,5-trimethylbenzene) to 16 with 89% selectivity. The
reaction was performed at the 50 mL scale with 4 mM
[substrate] using cell-free extract (CFE) and represented a 230-
fold improvement in activity over wt P450BM3.33
Rousseau and co-workers assessed P450BM3 libraries for the
hydroxylation of 4-phenylbutan-2-one 17 to give raspberry
ketone (4-(4-hydroxyphenyl)-2-butanone) 18 (Scheme 5).34
Mutants which performed well in an indigo oxidation screen
showed good correlation with improved hydroxylation activity,
and mutant A82Q gave 90 μM min−1 18 from reactions
containing 5mM [substrate] at the 50mL scale. A further screen
of P450BM3 mutants by Le and co-workers revealed variant
M16 V2-387, which catalyzed selective C3′ hydroxylation of the
stilbene polydatin 19 to form the catechol (E)-astringin 20, with
39-fold improvement over the parent M16 V2 variant.35
P450BM3 mutant “M13” was mutated to “M13” I86C/P18W,
which displayed improved regioselectivity in the hydroxylation
of the isoflavone genistein 21 to 3′hydroxygenistein 22 over its
8-isomer in a ratio of 12:1 compared to 1:1 for the wt.36
Scheme 3. Regioselective Hydroxylation of Steroids by
P450BM3 Mutants
Scheme 4. Hydroxylation of Aromatic Compounds by
P450BM3 Mutants
Scheme 5. Hydroxylations of Further Aromatic Compounds
by P450BM3 Mutants
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Miscellaneous Aliphatic Hydroxylations by P450BM3
Variants
Reetz and co-workers exploited large P450BM3mutant libraries
to create a catalyst for the selective hydroxylation of 6-
iodotetralone 23, focusing on the hotspot F87 position.37
Mutant F87V was 99% regioselective and gave the (R)-product
24with 36% yield and 98.7% ee at the 108 mg scale (Scheme 6).
Schulz and co-workers used mutant F87V/A328I as the first
catalyst in a two-step synthesis of nootkatone, in which
(+)-valencene 25 was transformed to mixtures of cis- 26 and
trans-nootkatol 27, achieving 221 mg L−1 of the final product at
the 20 mL scale.38 Pietruszka and co-workers screened 65
P450BM3 variants for the enantioselective allylic hydroxylation
of ethyl-6-heptenoate.39 Mutant A74G/L188Q transformed the
substrate to the (S)-alcohol with 90% selectivity over the
terminal epoxide and with 95% ee, enantioselectivity that was
also conserved for longer substrates from ethyl-7-octenoate to
ethyl-10-undecanoate. Isolated yields of between 23 and 45%
were obtained at the 60 mL scale employing 0.6 mmol substrate
and pure enzyme. Further studies by the group focused on the
enantioselective benzylic hydroxylation of benzoic acid
derivatives by P450BM3 variants in pursuit of phthalide and
isocoumarin products.40 Methyl-2-ethylbenzoate 28 was con-
verted to isocoumarin 29 with (R)- or (S)-selectivity using the
R47Y or F87V/L188Q variants, respectively, with 79 and 70%
conversion. The reaction with R47Y was scaled up to 2.20 mmol
in 210mL to give the (R)-product in 32% isolated yield and 66%
ee.
Arnold and co-workers applied BM3 variant “8C7” to the
selective oxidation of molecule 30 to give hydroxylated
intermediates that are the direct precursors to the alkaloid
nigelladine A 31.41 A lysate of E. coli was used for a 160 mg scale
oxidation of 30, the products of which were subsequently
oxidized to 31 using Dess−Martin periodinane in 21% yield
after two steps. Arnold also reported the engineering of another
redox self-sufficient P450, P450LA1 from Labrenzia aggregata, for
the oxidation of styrene.42 Ten rounds of directed evolution
were successful in changing the selectivity of P450LA1 from a
45:55 ratio of styrene oxide/phenacetaldehyde to 19:81 for the
anti-Markovnikov product. This “aMOx” variant was coupled
with an alcohol dehydrogenase for the “redox hydration” of
alkenes 32, 34, and 36 at the 40−60 mg scale to alcohols 33, 35,
and 37, respectively, in the last case with an er of 99:1 (Scheme
7).
Larger-Scale Hydroxylations by P450BM3 Variants
The experiments described above show that screening was
successful at identifying variants with altered selectivities, but
oxygenations using in vitro P450BM3 rarely yielded products
above the tens to hundreds of milligrams scale. However, if
process factors, including substrate concentration and oxygen
delivery, are considered together, gram-scale processes are
achievable. Liese and co-workers used CFE containing mutant
R47L/F87V/L188Q, coupled with glucose dehydrogenase
(GDH) for NADPH recycling, to construct a scalable in vitro
system for the hydroxylation of α-ionone.43 In studying factors
such as the addition of cosolvents and detergents, oxygen supply,
and the amount of enzyme, 1 L scale transformations of the
substrate were achieved with a productivity of 4100 mol
product/mol enzyme. The enzyme was applied in a bubble
aerated stirred tank reactor (Figure 2) at 15 mM [substrate]
with 5% methanol and an air-flow rate of 100 mL min−1 to give
97% conversion.
Nidetzky and co-workers established a gram-scale ω-2
hydroxylation of dodecanoic acid by wt P450BM3 and GDH
using either soluble enzymes or coimmobilization onto Relisorb
SP400 beads.44 P450BM3 was not stable on the carrier, so
soluble enzymes were selected for application in a 500 mL
reaction supplied with 80 mM (16 g L−1) substrate in 10%
DMSO, using a feeding strategy based on oxygen feedback
control. A TTN of 40 000 was achieved, giving a space-time
yield (STY) of 0.6 g L−1 h−1 and 7.1 g of isolated product in 92%
purity.
Whole-Cell Bacterial Systems Expressing P450s
The limitations of applying in vitro preparations of P450s for
scalable oxygenations has dictated that, with notable excep-
Scheme 6. Miscellaneous Aliphatic Hydroxylations by
P450BM3 Mutants
Scheme 7. “Redox Hydration” of Alkenes by the aMOx
Variant of P450LA1 Coupled with an Alcohol Dehydrogenase
(ADH)42
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tions,43,44 whole-cell systems have been the major focus of study
for larger reactions. Many of these again use either wt or variants
of P450BM3.
The best recent example of this was presented by DSM, who
produced the highest yielding P450BM3-catalyzed hydroxyla-
tion using a recombinant system.45 Freeze-fractured cells of E.
coli expressing wt P450BM3 and a GDH for NADPH-recycling
were employed for the regio- and enantioselective hydroxylation
of isophorone 38 to 4-hydroxy α-isophorone 39 (Scheme 8) at
the 100 L scale, permitting access to a hundreds of grams yield of
product. Key to the success of this approach was screening
reaction conditions at both the 20 mL and 1 L scales with an
oxygen flow of 0.6 L h−1, in order to maximize oxygen
availability. The largest transformations were performed at the
100 L scale in a 200 L fermentor, using cells derived from a 1000
L fermentation, with a stirrer speed of 140 rpm and an oxygen
flow of 72 L h−1. Substrate at 6 g L−1 was added, and a
productivity of 1 g L−1 h−1 was achieved, giving conversions of
80 and 82% and yields of the product of 51% and 61% with 99%
ee, respectively.
Bacterial Whole-Cell Hydroxylations of Steroids
Reinen and co-workers screened P450BM3 libraries in vitro for
the hydroxylation of the contraceptive norethisterone (NET) 40
(Scheme 9).46 Mutants “MT80” and “MT102” catalyzed
regioselective transformations to 16-β-hydroxNET 41 and
15β-hydroxyNET 42, respectively. Using whole cells of E. coli
in a 1 L fed-batch system and with carbogen (80% oxygen, 20%
carbon dioxide) as the oxygen supply, variant MT80 gave 47.6
mg L−1 of the 16β product 41, whereas M102 gave 308.7 mg L−1
of the 15β product 42, each with 99% regioselectivity.
Further transformations of steroids using P450BM3 variants
employed Rhodococcus erythropolis as the host, as steroid uptake
was thought to be superior in this strain.47 Following the
identification of the P450BM3 mutant “MO2” for the
conversion of norandrostenedione 43 to its 16β-hydroxylated
derivative 44, this was expressed in R. erythropolis, and the
recombinant strain produced 0.35 g L−1 44 from 1 g L−1 43 at
the 25 mL scale.
Bacterial Whole-Cell Aromatic Hydroxylations
Chu and co-workers used P450BM3mutants expressed in E. coli
for the biotransformation of the flavonoid naringenin 45
(Scheme 10).48 Mutant “M13” catalyzed the 3′-hydroxylation
of 45 at 100 μMconcentration at the 3 L scale to give eriodictyol
46 with 50% conversion and 13.5 mg L−1 yield.
P450Rhf is a redox self-sufficient P450 of different structural
organization to BM3, but which retains the advantages of a fused
reductase-heme domain structure. Whole cells of E. coli
expressing P450Rhf were applied to the 5′-hydroxylation of
the anti-inflammatory compound diclofenac 47 (Scheme 10) in
a fermentor at the 1 L scale,49 using a substrate concentration of
0.3 g L−1, with further additions of 0.1 g L−1 at 8 and 23 h. A
product concentration of 0.36 g L−1 was achieved after 30.5 h at
a rate of 11.7 mg L−1 h−1 and gave yields of 220−240 mg.
Miscellaneous Aliphatic Hydroxylations by Bacterial Whole
Cells
The use of whole cells facilitates the deployment of “Class I”
bacterial P450s that require FdR, Fd, and the heme domain for
activity, through coexpression of these proteins in the whole-cell
host. Ogawa and co-workers constructed a strain of E. coli
expressing the Class I P450nov and cognate Fd and FdR from
Novosphingobium sp. SB32149 for the conversion of the metal
Figure 2. Reactor for α-ionone hydroxylation by the R47L/F87V/
L188QP450BM3mutant. (a) Automatic titration device consisting of a
pHmeter and base titrator; (b) stirred tank batch reactor with a heating
jacket; (c) reflux condenser; (d) bubble aeration via sintered frit; (e)
gas washing bottle filled with water; (f) mass flow controller; (g)
pressurized air connection. Reproduced with permission from ref 43.
2016, Elsevier.
Scheme 8. Hydroxylation of Isophorone by E. coli Expressing
wt-P450BM3a
aGDH = glucose dehydrogenase.
Scheme 9. Hydroxylations of Norethisterone 40 and
Norandrostenedione 43 by P450BM3 Mutants Expressed in
E. coli and R. erythropolis
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chelating compound 49 (BMAL) to 3-benzyloxy-2-hydrox-
ymethyl-4-pyrone 50 (BMAL−OH) (Scheme 11).50
Two rounds of directed evolution gave a four-point mutant
that was used in a 100mL scale reaction, in which 5.2 g L−1 of the
product 50 was produced from 8 g L−1 49 in a 250 mL
fermentor. In a similar fashion, CYP154E1 from Thermobif ida
fusca was expressed in E. coli with PdX and PdR to create a
system for the hydroxylation of Grundmann’s ketone 51 to its
25-hydroxy derivative 52.51 In 5 mL scale reactions, a
concentration of 2 mM substrate yielded 1.1 mM product
after 24 h. CYP154E1 was aĺso engineered to oxidize (R)-
ketamine 53 to the antidepressant (2R,6R)-hydroxynorket-
amine 54 via two-step N-demethylation and hydroxylation.52
Mutagenesis yielded variant I238Q/L289T/M388A, which,
when expressed in E. coli, was used at the 10 mL scale at 5 mM
[substrate] to give 12 mg product with 50% yield. The Class I
enzyme P450pyr from Sphingomonas sp. HXN-200 was
engineered by Li and co-workers to create mutants for the
subterminal oxygenation of n-octane.53 One variant, A77Q/
I83F/N100S/F403I/T186I/L302 V (P450pyrSM1), expressed
in E. coli, hydroxylated octane to (S)-octanol with 99%
selectivity and 98% ee at 5 mM concentration at the 10 mL
scale. A further variant, I83F/N100S/T186I/L251 V/L302 V/
F403I (P450pyrSM2) hydroxylated propylbenzene to (S)-1-
phenyl-2-propanol with 98% selectivity and 95% ee on the same
scale. A double mutant of P450pyr, I83M/I82T, identified from
a screen of mutants targeting 22 residues, hydroxylated butanol
to butanediol, again at 5 mM substrate and on a 10 mL scale.54
Bacterial Whole-Cell Hydroxylations Using CYP153
Enzymes
Class I P450s of the CYP153 family have been the focus of
several studies, as they have potential for the hydroxylation of
alkanes and fatty acids. A variety of solutions to their electron
transport requirements and cofactor provision have been
explored. Hauer and co-workers fused the P450BM3 reductase
domain to the G254A mutant heme domain of CYP153A from
Polaromonas sp. JS666 (CYP153AP.sp.), which displayed
activity for the hydroxylation of butane to 1-butanol.55 Cells
of E. coli expressing the fusion protein oxidized gaseous butane,
in a pressurized reactor at 15 bar, used to increase butane
solubility (Figure 3). Using 61.2 mM butane, 4.35 g L−1 1-
butanol was produced with 96% selectivity. Hauer also
employed a fusion of the CYP153 heme domain from
Marinobacter aquaeolei with the P450BM3 reductase in a
whole-cell system for the ω-hydroxylation of dodecanoic
acid.56 Process limitations included substrate and product
inhibition, biocatalyst stability, and cofactor supply. Introduc-
tion of the substrate in the solid form helped to address issues of
substrate solubility, and in a 1 L bioreactor >5 mM product was
obtained from 10 mM substrate.
A CYP153 homologue from Polaromonas sp. JS666 was
coexpressed in Pseudomonas putida KT2440, with Fd, FdR and a
hydrogenase that converts NAD+ to NADH at the expense of
hydrogen.57 Cells of P. putida were challenged with 15% octane
and produced 101 mg L−1 1-octanol, although octanal and
octanoic acid were also produced. In an alternative approach to
cofactor provision, Harrison and co-workers coexpressed
CYP153A6 with Fd, FdR, and a glycerol dehydrogenase in E.
coli and evaluated the system for the hydroxylation of octane to
1-octanol.58 The use of mechanically permeabilized cells
expressing all enzymes gave a catalyst with which a product
titer of 61 mM was achieved, attributed to improved mass
transport in the absence of the cell membrane. Substrate
transport through the cell membrane was also addressed by Park
and Choi, who coexpressed CYP153A fromM. aquaeoleiwith an
Fd and FdR but also FadL, a long chain fatty acid transporter, in
E. coli deletion strain BW25113, in which beta-oxidation is
blocked.59 The whole-cell system was then challenged with
dodecane. Coexpression of the FadL protein increased the
concentration of the product α,ω-dodecanediol from 0.12 to
0.69 mM, giving 178 mg L−1 from 20 mM dodecanol at a rate of
56 mg L−1 h−1. Effective substrate transport was also targeted by
Lee and co-workers, who transferred the CYP153A operon from
M. aquaeolei, which included genes encoding the cognate Fd and
FdR, to E. coli, in combination with the AlkL alkane transporter
from P. putida.60 In a 5 L bioreactor containing 2 L of cell
culture, and following addition of 200 mL of either dodecane or
tetradecane, 1.5 and 2 g L−1 1-dodecanol and 1-tetradecanol,
respectively, were produced in 20 h with a dissolved oxygen level
of 40%.
Bacterial Whole Cell Hydroxylation of Cyclohexane
Buhler and co-workers have explored the application of a P450
from Acidovorax sp. CHX100 and its cognate Fd and FdR in the
Scheme 10. Aromatic Hydroxylations by Whole Cells of E.
coli Expressing P450s
Scheme 11. Miscellaneous Aliphatic Hydroxylations by Class
I P450s Expressed in E. coli
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oxygenation of cyclohexane to cyclohexanol. In one study, the
three proteins were coexpressed in Pseudomonas taiwanensis
VLB120.61 A resting cell activity of 20 U g−1 cell dry weight
(CDW) was recorded for the strain when challenged with 100
mM cyclohexane. The substrate was found to permeabilize the
cells, reducing activity, but introducing it through the gas phase
improved biocatalyst stability. Biocatalyst performance was
improved by strain engineering,62 through altering the ribosome
binding site (RBS) for the P450 gene, changing the plasmid copy
number, and introducing a terminator to reduce “leaky”
expression. This enhanced P450 expression improved the
activity from 20 to 55 U g−1 CDW, permitting a yield of
82.5% from 5mM cyclohexane. In the interest of creating a light-
driven system for the cyclohexane oxidation, the same group
cloned and expressed Acidovorax P450, Fd, and FdR in the
photosynthetic cyanobacterium Synechocystis sp. PCC6803.63 In
this system, both oxygen and the reduced cofactors would be
provided by photosynthetic water oxidation. Small-scale
reactions at 5 mM [cyclohexane] resulted in specific activities
of 26 U g−1 CDW at 150 μmol photons m−2 s−1. Efficiency was
improved using a two-phase system in which cyclohexane was
supplied as a 20% solution in diisononyl phthalate (DINP),
resulting in a maximum specific activity of 39 U g−1 CDW.
Cyclohexane oxidation was then performed in a stirred-tank
photobioreactor at the 1.2 L scale in a nonaerated two-phase
system, giving a product yield of 2.6 g L−1.
Whole-Cell Yeast and Fungal Systems Expressing P450s
While bacterial systems are attractive in terms of manipulatable
genetics and growth rates, it is clear that some eukaryotic P450s,
including human P450s, may benefit from expression in
eukaryotic hosts such as yeasts and fungi, in which the natural
P450 systems comprise a CPR and P450 domain.64 It is also true
that the most successful scalable hydroxylation reactions have
traditionally been carried out in whole cell yeasts or fungi, in
many cases engineered using conventional strain improvement
(CSI). The competition faced by recombinant P450 systems
from native yeasts and fungi is illustrated by the biotransforma-
tion of decanoic acid methyl ester (DAME) by Candida
tropicalis, reported by Schmid and co-workers.65 The first step in
oxidation of DAME to dodecanedioic acid is a terminal
hydroxylation by a native P450, CYP52A, and a CPR, each
induced by the addition of substrate. Careful manipulation of the
substrate feed rate and pH gave a yield of 66 g L−1 of the product
on a 300 mL scale. Inspired by the catalytic performance of such
strains, a range of approaches has been adopted toward the
optimization of recombinant yeasts, with a view to emulating
these productivities.
Whole-Cell Hydroxylation Using Recombinant
Saccharomyces cerevisiae
Recombinant expression in yeasts such as S. cerevisiae is a
common strategy. For example, the steroid 14α-hydroxylase
from Cochliolobus lunatus, P450lun, and its cognate CPR, were
expressed in S. cerevisiae, creating a strain that catalyzed the 14α
hydroxylation of androstenedione with 99% selectivity and 150
mg L−1 yield from a 250 mg L−1 substrate feed on a 20 mL
scale.66 Yun and co-workers expressed two P450s from Fusarium
oxysporum, FoCYP539A7 and FoCYP655C2 in S. cerevisiae, with
CPRs from the host strain, but also C. albicans and the cognate
CPR from F. oxysporum.67 The recombinant strains catalyzed
the ω-hydroxylation of C8−C12 saturated fatty acids, with
yields of 36−58 mg L−1 but only when using a deletion strain of
S. cerevisiae in which the acyl CoA oxidase gene Pox 1 was
removed. The best strain contained the FoP450s and the
cognate CPR. The same group improved the performance of the
strain expressing FoP450s by coexpressing FoCYP53A19 with
FoCPR and a GDH to improve cofactor supply for the P450
system.68 Cells of the recombinant strain converted 0.5 mM
benzoic acid to 0.47 mM benzoic acid (94% conversion) with
careful control of glucose concentration and pH.
Chen and co-workers optimized promoter combinations for
the expression of mutants of P450 SmF3′H from Silybum
marinarum and its cognate CPR in S. cerevisiae, to create a
biocatalyst that catalyzed the 3′ hydroxylation of (2S)-
naringenin to eriodictyol with yields of up to 3.3 g L−1 on a
2.5 L scale.69 The related flavonoid chrysin 55 (Scheme 12) was
also hydroxylated by a recombinant strain of S. cerevisiae, in this
case expressing human CYP1A1, to give the 6-hydroxylated
product baicalein 56 at the 100 mg scale at 2 mM [substrate]
with 92% conversion.70
Figure 3. Schematic illustration of the apparatus used for the hydroxylation of gaseous butane by G254A mutant heme domain of CYP153A from
Polaromonas sp. JS666. Reproduced with permission from ref 55. 2014, Elsevier.
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To address the issue of insufficient cofactor supply to the
P450 in an S. cerevisiae system, Zhang and co-workers developed
a bioelectrocatalytic system in which electricity is used to recycle
the reduced nicotinamide cofactor via external electron transfer,
using neutral red (NR) as an electron shuttle.71Using a strain in
which CYP7B1 had been expressed, for the purpose of
hydroxylating DHEA to 7α-OH-DHEA, 290 mg L−1 of product
resulted from 400 mg L−1 substrate at the 140 mL scale, a
productivity 2.4-fold greater than that achieved in the absence of
NR.
Whole-Cell Hydroxylation Using Recombinant P. pastoris
P. pastoris presents another option for heterologous expression
of eukaryotic P450s as another genetically well characterized
system used routinely for recombinant protein production. P450
STH10 and its cognate CPR from Thanatephorus cucumuris
were identified as being able to hydroxylate steroids in the C-19
position. Coexpression of the genes in P. pastoris gave a strain
that hydroxylated 1mM11-deoxycortisol 57 (Scheme 12) at the
500 mL scale, to give 19-hydroxy-11-deoxycortisol 58 and 11β-
hydroxy-11-deoxycortisol 59.72 Further P450s from this
organism, CYP5150AP3 and CYP5150AN1, were also ex-
pressed with a CPR in P. pastoris and exhibited 7β- and 2β-
hydroxylation activity toward 57 on the same scale.73 Pichia is
also a suitable host for human P450s such as CYP3A4. Glieder
and co-workers performed the gram-scale hydroxylation of
testosterone using cells of P. pastoris expressing CYP3A4 and
human CPR.74 In 1.3 L of medium, 959 mg of substrate yielded
108 mg (11.3%) of 6β-hydroxytestosterone and 87 mg of 6β-
hydroxyandrostenedione (9.1%) as the major products.
The construction of a chimeric fusion protein based on
CYP105D7 permitted the creation of a Pichia strain competent
for the 3′ hydroxylation of genistein to 3′-hydroxygenistein.75
The P450 was N-terminally fused to the transmembrane domain
of CYP57B3 from Aspergillus oryzae and C-terminally fused to
the CPR from S. cerevisiae. The strain converted substrate to
product on a 2.5 L scale using 100 μM substrate, with a yield of
15 mg L−1.
Improvement of Pichia for hydroxylations has not been
restricted to engineering of the P450 genes. Transcriptome
analysis of Pichia engineered to express valencene synthase,
Hyoscyamus muticus premnaspirodiene oxygenase (HPO), and a
P450 reductase (PpHCV) revealed upregulation of a homo-
logue of SaccharomycesDNA repair enzyme RAD52.76 In a strain
in which RAD52 was overexpressed, the production of trans-
nootkatol from valencene was elevated from a 20 to 40 mg L−1
cell culture at the 50 mL scale. When combined with
optimization of organism cultivation, yields of 98 mg L−1
culture were obtained.
Whole-Cell Hydroxylation Using Engineered Fungal Strains
Given the history of scalable hydroxylations using fungi, it is
unsurprising that contemporary methods have been applied to
these organisms to alter or improve hydroxylation reactions. A
strain of Aspergillus ochraceus M018, which catalyzed the 11α-
hydroxylation of canrenone 60 (Scheme 13), was improved
through homologous expression of the relevant P450, under the
control of the Tr promoter, to create strain M010.77 Cells of the
mutant strain, when challenged with 20 g L−1 of the substrate,
gave 93% conversion to product 61 after 60 h compared to 75%
after 96 h for the M018 strain. The hydroxylation of 16α,17-
epoxyprogesterone (EP) 62 to 11α-hydroxy-16α,17-epoxypro-
gesterone (HEP) 63 by a native strain of Rhizopus nigricans
ZXPO1was enhanced by the heterologous expression within the
strain of the glucose-6-phosphate dehydrogenase from Rhizopus
oryzae.78 Both biomass and biotransformation yields were
increased, with a conversion of 38% after 52 h compared to 30%
by the native strain, when challenged with 5 g L−1 EP at the 50
mL scale. Further attempts to increase cofactor provision were
undertaken by Xu and co-workers, who increased productivity of
7α,15α-dihydroxydehydroepiandrosterone from DHEA by
coaddition of the cofactor precursor nicotinic acid and 15 g
L−1 glucose.79 This raised productivity by approximately 75%
compared to controls. A fed-batch transformation with three
sequential additions of 5 g L−1 of substrate gave 11.21 g L−1 of
product after 60 h.
Protein and strain engineering were combined in a study of
pravastatin production by Pencillium chrysogenum.80 The
compactin biosynthetic pathway from Pencillium citrinum was
first introduced into P. chrysogenum, along with a gene encoding
a fusion of P450 CYP105AS1 from Amycolatopsis orientalis with
the reductase domain of P450 Rhf, with the objective of
stereoselective hydroxylation of compactin. However, the P450
Scheme 12. Hydroxylations by Recombinant Yeasts
Expressing P450s
Scheme 13. Hydroxylations by Engineered Fungal Strains
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gave the opposite epimer, epi-pravasatin, to the one required, so
enzyme engineering was performed to give mutant P450prava that
hydroxylated compactin 64 with the required stereoselectivity
(Scheme 13). P. chrysogenum expressing both the compactin
pathway and the P450prava fusion protein were used in a 10 L fed-
batch fermentor for the production of pravastatin 65 with yields
of up to 6 g L−1.
■ P450s ACTING IN A PEROXYGENASE MODE
Some of the complexities in the use of P450s can be addressed by
exploiting their ability to act in a peroxygenase mode where,
rather than generate Compound I through the delivery of
electrons to the heme domain fromNAD(P)H, the iron(IV) oxo
species is generated directly using H2O2, exploiting what is
known as the “shunt” pathway. Previous studies established that
P450s, such as the heme domain of P450BM3, can be evolved
for the improvement of peroxide driven biotransformations.17
More recently, using P450BM3, Nguyen and co-workers created
a nine-point mutant for the 4’-hydroxylation of atorvastatin
using only H2O2,
81 although interestingly, the whole P450BM3
protein outperformed the heme domain in isolation. Further
developments to the P450BM3 system for peroxide driven
oxygenations employed a “dual function small molecule”
(DFSM) approach,82 in which N-(w-imidazol-1-yl hexanoyl)-
L-phenylalanine (Im-C6-Phe) is bound in the P450 active site so
as to provide the imidazole side-chain as an acid−base catalyst,
designed to mimic a homologous glutamate in UPOs, which use
H2O2 as their natural route to Compound I. When Im-C6-Phe
was included with mutant F87A/T268I/A184I in a biotrans-
formation of propane, turnovers were 2-fold higher than had
been recorded for UPOs with that substrate. This peroxygenase
activity of P450BM3 was subsequently extended to the
regioselective demethylation of methoxy-substituted aromatics
using the DFSM technique;83 mutant F87A/T268I, in
combination with Im-C5-Phe, gave a TON of 486 for the
demethylation of anisole to phenol.
In addition to engineered peroxygenase activities, a family of
P450s for which the natural mode of Compound I formation is
through peroxide, has been described relatively recently.18,19
“P450 peroxygenases”, which include the enzyme OleT from
Jeotgalicoccus sp. 8456,84 catalyze both the hydroxylation and
decarboxylation of fatty acid substrates. The activity depends
upon the formation of a salt-bridge between the carboxylic acid
of the substrate and an arginine residue in the active site. This
limits the substrate range of P450 peroxygenases, although
native enzymes with the ability to enantioselectively oxidize
styrenes to styrene oxides have been reported, including
CYP119 from Sulfolobus acidocaldarius.85 These have been
improved using site-directedmutagenesis, with ee’s of up to 91%
reported for the epoxidation of cis-β-methylstyrene, although
only on analytical scale.86,87Despite these advances in theH2O2-
driven peroxygenase activity of P450s, the use of peroxide to
drive hydroxylations is best effected in Nature by unspecific
peroxygenases (UPOs).
■ UNSPECIFIC PEROXYGENASES (UPOs)
Unspecific peroxygenases (UPOs)8,9 are a class of secreted
fungal hemoproteins that catalyze the oxygenation of organic
substrates at the expense of H2O2 only and hence have no
requirement for NAD(P)H or electron transfer proteins, in part
addressing the “oxygen dilemma” (the dependence upon
oxygen, balanced against the harmful ROS formation created
during uncoupling processes) contextualized by Holtmann and
Hollmann.88 This simplicity, coupled with high activity and
stability, makes UPOs attractive alternatives to P450s for
scalable oxygenations if systems could be facilitated for their
heterologous expression and their activities engineered. Since
their description by Hofrichter and co-workers,20 researchers
have suggested that there are two major groupings of UPOs:
“short” enzymes of approximately 29 kDa molecular weight,
typified by MroUPO from Marasmius rotula,89 and “long”
enzymes of 44 kDa, typified by the AaeUPO from Agrocybe
aegerita,20 the most studied UPO. While only a few UPOs from
fungi have been identified and partially characterized, a larger
study of their distribution90 in Nature revealed a large number of
homologues, grouped in five subfamilies, the activities of which
may provide valuable diversity.
Oxygenations with wt UPOs
The activity of UPOs expressed from fungi, or in a recombinant
A. oryzae system, had already revealed an interesting diversity of
substrate specificity. Four peroxygenases displayed different
selectivity toward the oxidation of 40 mM cyclohexane, with
MroUPO giving a 1.61:0.93 mM ratio of cyclohexanol to
cyclohexanone. AaeUPO, by contrast, yielded a 3.05:0.05 mM
ratio for these products.91 Wt AaeUPO was also reported to
catalyze the oxygenation of 3.5 mM sulfides at the 3.5 mL
scale.92 Thioanisole was converted to its (R)-sulfoxide with 95%
conversion and 80% ee, although ee’s were improved for vinyl
thiobenzene with values of >99%.
The selectivity of MroUPO for alkane hydroxylation was
superior to that of AaeUPO, giving largely terminal hydrox-
ylation of dodecane and tetradecane at a 0.3 mM concentration
in 20% acetone to products with conversions of between 48%
and 65%. AaeUPO gave primarily subterminally oxygenated
products.93MroUPO also catalyzed the chain-shortening of fatty
acids through hydroxylation and oxidation in the α-position. In
one example, MroUPO, challenged with 0.1 mM decanoic acid
at the 1−5 mL scale, gave nonanoic acid, although other
products, including the α-hydroxyl-, α-keto, and diterminal
acids, were also obtained.94 UPOs from Marasmius spp. were
also found to catalyze side-chain removal from steroids such as
cortisone95 through oxidation at C21 to form a gem-diol,
followed by formation of a carboxylic acid. This underwent bond
fission at C17 to yield adrenosterone as the major product with
70% yield from the 80 mg scale in 50 mL. AaeUPO was inactive
toward this substrate, attributable to its narrower and longer
heme access channel. In another steroid transformation, the
UPO from Chaetomium globosum (CglUPO) catalyzed the
oxygenation of testosterone to give both the 4,5-epoxide and
16α-testosterone in a 9:1 ratio, whereas neither AaeUPO nor
MroUPO converted the substrate.96 A 100 mg scale reaction in
approximately 200 mL of buffer gave 65 and 7 mg isolated yields
of the respective products. MroUPO was also found to be the
superior UPO among four including AaeUPO, CciUPO, and
CglUPO for the oxygenation of cyclophosphamide 66 (Scheme
14).97
At the 100 mL scale, 261 mg of 66 was transformed to 4-
hydroxycyclophosphamide 67 in 32% yield when peroxide was
delivered at 5 mM h−1, with only a small amount of the
overoxidized 4-keto metabolite produced. These UPOs
displayed very different selectivities for the oxygenation of
trans-stilbene 68, giving 100% conversion to the dihydroxylated
4,4′-dihydroxy stilbene 69, except CglUPO which epoxidized
the double bond to give product 70 with 100% selectivity.98
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CglUPOwas alsomost selective for the epoxidation of fatty acids
and fatty acid methyl esters, giving between 91 and 99%
selectivity for the epoxidation of C14 to C20 cis-fatty acids,
whereas other UPOs gave mixtures of epoxidized and
hydroxylated products.99 Issues with selectivity were again
observed with the transformation of 1,2-dihydronaphthalene by
AaeUPO and CraUPO.100 In analytical scale reactions, 2 mM
substrate underwent epoxidation to yield the epoxide with 32%
ee, but additional hydroxylation led to the naphthalene hydrates
2-hydroxy- and 1-hydroxy-1,2-dihydronaphthalene, which were
subsequently aromatized, and then hydroxylated, to give
naphthols. These examples illustrate the promise of UPO-
catalyzed oxygenations, but also one of their limitations, which is
the lack of selectivity when presented with some compounds
with carbon atoms that are equally susceptible to oxygenation.
Heterologous Expression of UPOs
One obstacle to scalable oxygenations using UPOs was their lack
of availability, which in the research above depended upon their
isolation from the culture medium of the relevant fungus. The
development of heterologous systems for enzyme production
therefore greatly facilitated their large-scale application, and also
their engineering. An expression system using Aspergillus niger,
which furnished enzymes for some of the studies described
above, was patented by Novozymes in 2008.101 In 2014, Alcalde
and co-workers reported the first expression of AaeUPO in both
S. cerevisiae and P. pastoris102 First, the heterologous expression
of the AaeUPO gene enabled the construction of a directed
evolution platform from which 9000 clones were assessed for
improved expression and activity,103 resulting in a variant, PaDa-
I, with nine point mutations from the wild-type sequence, which
exhibited 1114-fold improved expression and 3250-fold
improved activity. This variant contained four mutations in
the signal sequence that promotes enzyme secretion, as well as
fivemutations within the enzyme itself: V57A/L67F/V75I/I248
V/F311L. Of these, structural studies showed that F311L
enlarged the entrance to the heme channel from 8 to 12 Å,
increasing substrate access to the heme.104
The gene encoding PaDa-I was transferred for expression in P.
pastoris with an activity of 232 000 U L−1 or 217 mg mL−1, now
constituting a robust platform for enzyme production.103 S.
cerevisiae continued to provide a platform for further directed
evolution of AaeUPO. This included subjecting the PaDa-I gene
to “neutral drift” experiments designed to elicit mutants with
improved thermostabilities and tolerance to organic solvents,
resulting in an improvement in t1/2 for one mutant of 34 min and
improved tolerance to acetonitrile as a reaction cosolvent.105
Further experiments resulted in variants for which the
peroxygenase/peroxidase activity ratio of AaeUPO was
improved.106 Positions T120 and T320 were most significant
in this case, with 4-fold increases in peroxygenase: peroxidase
activity ratio obtained when mutations T120V and T320N(R)
were coupled with mutation S226G, which had demonstrated
improved thermostability over the PaDa-I variant.
These platforms for UPO evolution permitted further
engineering of these enzymes. Another variant created from
PaDa-I, with additional mutations G241D/R257K and named
JaWa, displayed an improved ratio of peroxygenase/peroxidase
activity107 and also an improved selectivity of 97% for the
conversion of naphthalene to 1-naphthol over 2-naphthol
compared to PaDa-I. Further improvements were obtained by
mutating phenylalanines in the heme access channel to smaller
residues; 12−16% increases in activity were obtained when F76
was mutated to A or L in combination with F191A.108 Structure-
informed mutagenesis of JaWa permitted the creation of a
further mutant with an F191S mutation, SoLo, giving a 15-fold
improvement in the 99% regioselective transformation of
propranolol 71 to 5′-hydroxypropanolol 72 with 445000 TTN
(Scheme 15).109
In a 10 mL reaction, 50 mM propranolol was converted to 72
in 15.2% yield using tert-butyl hydroperoxide. Further drug
metabolites were generated using the SoLo variant in a similar
fashion.110Dextromethorphan 73was converted to dextrorphan
74 at the 136 mg scale in 100 mL to give a yield of 75.2%, with
activity also recorded for the demethylation of naproxen and the
hydroxylation of tolbutamide 75 to 4-hydroxymethyltolbuta-
mide 76, illustrating the utility of UPOs in the preparation of
drug metabolites.
Further work has enabled the rapid screening of expression
constructs in S. cerevisiae for UPO production. Weissenborn and
co-workers developed a modular tripartite system that permits
the shuffling of 17 signal peptide sequences, UPO genes, and C-
terminal tags encoding green fluorescent protein (GFP) variants
for optimal expression and detection of target UPOs.111 The
study revealed that optimal expression was sometimes obtained
for UPOs with their noncognate signal peptide sequence. In this
manner, UPOs from Myceliophthora thermophila (MthUPO)
Scheme 14. Some Oxygenations Catalyzed by Wt UPOs
Scheme 15. Oxidation of Pharmaceutical Molecules by
Mutants of AaeUPO
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and Thielavia terrestris (TteUPO) were expressed and
characterized, with MthUPO catalyzing the epoxidation of
styrene to give the (S)-epoxide product with 45% ee. Constructs
were also transferred to P. pastoris for improved enzyme
production. MthUPO produced in this way hydroxylated N-
phthaloyl-phenethylamine 77 (Scheme 16) to product 78 with
57% yield and 98.6% ee.
Failure to express in UPOs in an active form in E. coli had
meant that evolution using this more accessible system was not
possible. However, it was recently shown that some UPOs of the
“short” variety can indeed be expressed in E. coli, expanding the
possibilities of engineering these enzymes. Martińez and co-
workers expressedMroUPO in E. coli using a pET23a vector and
altered its specificity toward oleic acid using in silico analysis
coupled withmutation.112Thus, wtMroUPO, which produced a
large proportion of epoxidized product, was converted to the
I153F/S156 variant, for which the major products were
oxygenated in the ω-1 position. This mutant was later applied
to the 350 mL scale epoxidation of 0.1 mM α-linolenic acid to
the 15(R)-, 16(S)-monoepoxide with 67% yield and 83% ee.113
Similarly, two further “short” UPOs, from Collariella virescens
and Daldinia caldariorum, were also expressed in E. coli,
illustrating the general applicability of the method.114 The
Collariella UPO was mutated to an F88L variant, widening the
heme access channel and giving improved selectivity for the
oxygenation of linoleic acid, with reduced amounts of
hydroxylated products.115
Generating Hydrogen Peroxide for UPOs
With heterologously produced UPOs, rapid advances have now
been made in their application and also in process engineering
for scalable reactions.While many studies address new reactions,
the question of how best to generate H2O2, in such a way as to
not inactivate the UPO, has also been investigated (Scheme 17).
In many of the small-scale examples above, peroxide was
delivered slowly either through a syringe pump or in aliquots, so
as not to deactivate the UPO. To address the issue of peroxide
sensitivity, Hollmann and co-workers showed that H2O2 could
be generated in situ through the incorporation of an alcohol
oxidase from P. pastoris (PpAOx), which oxidized methanol to
formaldehyde with concomitant generation of H2O2.
116 More-
over, a formaldehyde dismutase (Fdmt) was incorporated into
the reaction, catalyzing the transformation of formaldehyde to
methanol and formic acid, increasing the turnover of methanol.
In this way, ethylbenzene was converted to (R)-1-phenylethanol
in 62% yield from a concentration of 50 mM. It also proved
possible to use the oxidation of formate for peroxide generation
through coupling a formate dehydrogenase with a flavin
dependent reductase, Yqjm, which generates peroxide as a
means of regenerating oxidized flavin in electron transfer
reactions.117
This system was improved through the application of formate
oxidase from A. oryzae (AoFox), which drove the production of
H2O2 not only through the oxidation of formate but also from
methanol, which served as the cosolvent in a selection of
peroxygenase-catalyzed oxygenations.118Hence, in the presence
of 10% (v/v) methanol and AoFox, AaeUPO catalyzed the
oxygenation of 100 mM ethylbenzene to (R)-1-phenylethanol
with over 30% conversion in 144 h. In a further development,
Alcalde and co-workers created a fusion of the AaeUPO SoLo
variant with the flavin-dependent aryl alcohol oxidase (AAO)
from Pleurotus eryngii, which generates peroxide as a byproduct
when converting aryl alcohols to aldehydes.119 A construct “H”,
in which the N-terminal UPO was connected to the C-terminal
AAO by a linker of 110 amino acids, was applied to the
biotransformation of dextromethorphan 73 shown in Scheme
15, but with the addition of 4-fluorobenzyl alcohol as the AAO
substrate for peroxide generation. The fusion displayed a 2-fold
increase in production of dextrorphan 74 after 15 min of
incubation, compared to a mixture of the individual enzymes,
suggesting improved substrate channelling within the fusion.
One way to address the peroxide supply without recourse to
additional enzymes is to exploit photocatalytic oxidation
reactions for the oxidation of water to H2O2.
120Gold-containing
titanium dioxide, when irradiated with visible light, catalyzed the
oxidation of water to H2O2, which was then used by AaeUPO to
hydroxylate ethylbenzene. To minimize enzyme inactivation,
AaeUPOwas immobilized on a poly(methyl methacrylate) resin
and used in combination with hydrophobic rutile Au-TiO2. This
gave a robust catalytic system with total turnovers increased
from 2000 to 21 000 over reaction times of up to 120 h. A range
of alkanes and cycloalkanes were converted to mixtures of
alcohols and ketones including a semipreparative reaction in
which 10 mM ethylbenzene was converted to the product with a
81% isolated yield and 97.4% ee. It was later determined that
increases in light intensity and temperature increased
productivity, but only up to the point at which these factors
caused denaturation of the enzyme owing to increased
Scheme 16. Hydroxylation of N-Phthaloyl-phenethylamine
by UPO from M. thermophila (MthUPO)111
Scheme 17. Selected Methods of Generating Hydrogen
Peroxide for UPO-Catalyzed Oxygenationsa
aUPO = unspecific peroxygenase; Fox = formate oxidase; PpAox = P.
pastoris alcohol oxidase; Fdmt = formaldehyde dismutase; PEC =
photoelectrochemical.
JACS Au pubs.acs.org/jacsau Perspective
https://doi.org/10.1021/jacsau.1c00251
JACS Au XXXX, XXX, XXX−XXX
L
generation of reactive oxygen species (ROS).121 Photocatalysis
was also used for reductive activation of oxygen using electrons
from water. A photoelectrochemical (PEC) tandem cell
structure, consisting of an FeOO/BiVO4 photoanode, a CIGS
solar cell, and a CN/rGO cathode, enabled first the oxidation of
water at the anode, followed by oxygen reduction at the cathode,
to give H2O2.
122 This was coupled to the AaeUPO-catalyzed
hydroxylation of ethylbezene again, giving a TTN of 43 300. A
further system employed flavin molecules immobilized on single
walled carbon nantotubes which, when irradiated with UV light,
stimulated the production of H2O2 from oxygen, enabling
AaeUPO-catalyzed hydroxylation of 100 mM ethylbenzene to
17 mM product over 50 h with a TTN of 123 000.123 Nitrogen-
doped carbon nanodots (N-CNDs) were used as an alternative
catalyst for photoactivated H2O2 generation.
124 If coimmobi-
lized with AaeUPO in alginate beads, this enabled the
hydroxylation of cyclohexane as a neat substrate when N-
CNDs and enzyme were applied in an 8:1 (mg/nmol) ratio,
enabling a TTN of 7806 and a yield of 2.25 mM cyclohexanol
over 96 h. Further transformations in neat media were achieved
with AaeUPO immobilized on the polyacrylic support
Immobead IB-COV-1, for the epoxidation of styrenes.125 At
the 10 mL scale with a tert-butoxide delivery rate of 5 mM h−1,
cis-β-methylstyrene was converted to 360 mM (1R,2S)-β-
methylstyrene oxide and with a TTN of 8500. AaeUPO was
also immobilized on PVA PEG gel beads and then applied to a
100mL scale stirred tank reactor for the transformation of 5 mM
diclofenac.126 In this way, 414 mg of 4′-hydroxy diclofenac was
produced with a TTN of over 61 000. Fe-glass EziG matrices
were also suitable supports for AaeUPO immobilization.127
Using AaeUPO with a C-terminal histidine tag, the enzyme was
immobilized and applied to the hydroxylation of 10 mM ethyl
benzoic acid with over 80% conversion, and could be reused for
multiple cycles.
Peroxide was also generated from hydrogen and oxygen in
water using AuPd catalysts at ambient pressure and at 40 bar,
which has the advantage of no ROS formation as with
photocatalysis.128 In 10 mL scale reactions using 10 mM
cyclohexane with 80% hydrogen and 20% air introduced
continuously at 2 bar and 2.5 wt % Au−2.5 wt % Pd/TiO2 as
a catalyst, TTNs of 25 300 were achieved with an 87% yield of
cyclohexanol in 16 h. Ethylbenzene at 20 mM was converted to
13.1 mM phenylethanol and 2.9 mM acetophenone in 16 h with
a TTN of 51 400, and a TTN of 201 000 was achieved through
sequential additions of 30 mM substrate to give 46 mM
phenylethanol and 14 mM acetophenone in 64 h. The
generation of H2O2 from oxygen was also addressed using an
electroenzymatic approach, which offers a highly atom
economical approach as it only requires oxygen, electrons, and
protons. In a glass reactor fitted with a gas-diffusion electrode,
H2O2 was continuously generated and supported the trans-
formation of ethylbenzene with a TTN of 400 000 at a current
density of −10 mA cm−2 and an STY of 13.2 g L−1 day−1.129
Scaled-Up Biotransformations Using UPOs
The potential of UPOs for scaled-up reactions was realized by
Liese and co-workers, who performed a 2 L scale oxygenation of
butane to butan-2-ol using AaeUPO.130 A bubble column
reactor permitted the controlled introduction of both H2O2 and
butane into the mixture at rates of 882 mM/136 mL h−1 and
61.4 L h−1 (Figure 4). Here, 8.5 g of 2-butanol and 5.6 g of
butanone were recovered from the experiment after 4 h with
overoxidation to butanone and biocatalyst stability being the
major issues.
The scale-up of UPO reactions will be facilitated by the ability
to produce the enzyme on a scale sufficient to furnish larger
oxidations. Tonin and co-workers reported the production of
AaeUPO at the 2480 L scale, which produced 170 g of the
recovered enzyme.131 The large amount of UPO produced
permitted its application to a 100 mL scale hydroxylation of
ethybenzene in a two-liquid-phase system, giving a product
concentration of 14.4 g L−1 in the organic layer after 7 days. The
application of UPOs in such systems will benefit from evolution
experiments targeted at increasing their stability to organic
solvents. Alcalde and co-workers showed that a variant of the
PaDa AaeUPO, WamPa, which features nine additional
mutations, displayed 23-fold greater stability in the presence
of 30% acetonitrile.132
■ SUMMARY
In this Perspective, we have surveyed recent advances in
biocatalytic oxygenations by hemoproteins, with an emphasis on
reactions that result in isolatable yields from the tens of
milligrams to, in one case,45 kilogram quantities. The range of
catalysts, from cell-free preparations, in soluble or immobilized
form, to permeabilized and intact cells, has encouraged
imaginative approaches to the optimization of each, with
specific considerations applied to their distinct challenges.
It is clear that protein engineering will continue to play a vital
role in the generation of new selectivities, but also in the creation
of more active and stable enzymes. For P450s, the evolution
methods have been facilitated through straightforward ex-
pression in E. coli. For UPOs, the examples are less well-
distributed, owing to current requirements for expression in
yeasts, but the development of these systems and also the
Figure 4. Experimental setup for butane oxygenation by AaeUPO in a
bubble column reactor (middle) coupled with an extractive column
(right). From ref 130. CC BY 4.0.
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encouraging work on the expression of active UPOs in E. coli
mean that the engineering of UPOs in the mode of P450s should
be more prevalent in the coming years.
The engineering of hemoproteins tailored for specific
reactions provides the raw material for process development
and scale-up. The requirement for both nicotinamide cofactors
and cofactor recycling remains a process complication for the
application of cell-free P450s, but examples in this survey43,44
show that consideration of factors that optimize substrate
solubility and oxygen delivery can furnish processes that can
deliver products on the gram to kilogram scale. However, it may
be considered that productivities are still substantially lower
than may be required, especially for the production of bulk
chemicals. It is also encouraging that some of the larger scalable
examples are not restricted to native substrates of P450BM3 but
include structurally unrelated compounds such as α-isophor-
one.45 The process stability of P450s is a persistent challenge for
cell-free reactions, but one that may conceivably be addressed by
further protein engineering or enzyme immobilization ap-
proaches. The expense of in vitro P450 processes, which is not
often quantified in academic papers, must also be considered
against the possibilities offered by whole-cell reactions that do
not require the supply of exogenous cofactor.
The complications of cell-free processes make whole-cell
P450 reactions appear attractive; therefore, their simplicity,
tolerance to higher concentrations of substrate, and consequent
superior productivities at scale65 suggest that these may be the
catalysts of choice for scalable oxygenations. However, over-
metabolism and side reactions with competing selectivity,
particularly in wt strains, can depress yields and complicate
downstream processing. Hence, the developments in the
expression and application of P450s in recombinant host strains
is very encouraging, although examples have shown that the
productivities of non-native enzymes within recombinant strains
can be reduced. These disadvantages can be addressed when a
whole-organism approach to strain engineering is adopted,69,76
and techniques such as CRISPR-Cas9, which is already being
used in yeasts133 and fungi134 for biotechnological applications
including those related to P450,135 should accelerate the
development of improved strains.
Given the process complications of P450s in vitro and the
complexities of strain engineering in the optimization of in vivo
reactions, UPOs present themselves as a simple and applicable
alternative for scalable reactions, especially in the chemical
laboratory. Despite their sensitivity to H2O2, the first scale-up
reactions are showing that, when peroxide delivery is addressed,
the enzyme can be deployed effectively for the gram-scale
generation of oxygenated products.130However, the examples in
this survey show that the lack of selectivity, in the form of either
overoxidation or oxygenation at multiple sites, is an ongoing
issue. The increasing availability of new UPO sequences and the
methods to engineer them suggest promising avenues for
exploration in a bid to acquire better and more diverse
selectivity.
In summary, given the advances in enzyme discovery,
molecular biology, and process biochemistry, hemoprotein
biocatalysts can still be considered to have considerable
potential for selective and sustainable oxygenation reactions.
However, the success of each reaction will depend strongly upon
the selection of the right enzyme or host organism and the mode
of oxygen or peroxide delivery. The stability of the biocatalysts in
question under process conditions must also be addressed, and
further work on enzyme engineering and biocatalyst formulation
will also be important targets of research in the future.
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